Lexeo Therapeutics, Inc. Common Stock
Financials
Valuation Metrics
Lexeo Therapeutics, Inc. Common Stock's Market Cap is $252M. At end of 2025 it was $606M. Ranked #2944 of 3,116 in US market (top 94%), #1337 of 1,472 on NASDAQ (top 91%), #240 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $252M | US#2,944/3,116 Sec#240/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-87M | US—/3,116 Sec—/265 |
| Total Assets | $255M | US#2,935/3,116 Sec#222/265 |
| Net Assets | $235M | US#2,612/3,116 Sec#173/265 |
| Employees | 59 | US#2,682/3,116 Sec#203/265 |
| Value | ||
| P/B | 1.07x | US#466/3,116 Sec#22/265 |
| FCF Yield | -35.21% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -37.12% | US#2,602/3,116 Sec#127/265 |
| ROA | -34.24% | US#2,907/3,116 Sec#170/265 |
| Financial Health | ||
| Debt Ratio | 8.44% | US#83/3,116 Sec#39/265 |
| Total Debt | $7M | US#2,860/3,116 Sec#208/265 |
| FCF | $-89M | US#2,618/3,116 Sec#138/265 |
| Cash | $93M | US#2,274/3,116 Sec#180/265 |
| Current Ratio | 13.89x | US#177/3,116 Sec#53/265 |
| Performance | ||
| 1Y Return | -69.33% | US#3,032/3,116 Sec#254/265 |
| 1M Return | -13.02% | US#2,591/3,116 Sec#195/265 |
| From 52W High | -72.06% | US#3,003/3,116 Sec#243/265 |
| 1Y MDD | -75.26% | US#2,995/3,116 Sec#240/265 |
| Trading | ||
| Volume | 1,074,121 shares | US#1,454/3,116 Sec#144/265 |
| Trading Value | $3M | US#2,766/3,116 Sec#225/265 |
| Per Share | ||
| EPS | $-1.06 | US—/3,116 Sec—/265 |
| BPS | $2.87 | US#2,497/3,116 Sec#162/265 |
Company Info
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.